您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > BI-882370
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
BI-882370
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
BI-882370图片
CAS NO:1392429-79-6
包装与价格：
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
BI-882370 是一种高效选择性的RAF激酶抑制剂，其结合位于 BRAF 激酶的 DFG-out 无活性构象处 (ATP 结合位点)。 BI-882370 抑制 BRAFV600E-mutant, WT BRAF 和 CRAF 激酶的IC50值分别为 0.4，0.8 和 0.6 nM。BI-882370 也可以抑制 SRC 家族激酶。
生物活性

BI-882370 is a potent and selectiveRAFkinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of theBRAFkinase. BI-882370 (BI 882370) inhibits the oncogenicBRAFV600E-mutant, the WTBRAFand CRAF kinases withIC50sof 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibitsSRCfamily kinases[1].

IC50& Target[1]

Braf

0.6 nM (IC50)

c-Raf

0.8 nM (IC50)

BRafV600E

0.4 nM (IC50)

体外研究
(In Vitro)

BI-882370 (0.9-6000 nM; 3 days) inhibits the BRAF-mutant human melanoma and colorectal cancer cells proliferation with a EC50range of 1-10 nM[1].
BI 882370 (0.1-100 nM, 0.1-3000 nM; 2 hours) results in a reduction of p-MEK1/2, p-ERK1/2 and cyclin D1/D2 expression in BRAFV600E-mutant A375 cells; induces phosphorylation of MEK1/2 and enhanced phosphorylation of ERK1/2 in WT BRO cells (3-300 nM)[1].
BI 882370 (0.1-100 nM, 0.1-3000 nM; 24 hours) suppresses cyclin D1/D2 expression, induces Kip1/p27 expression at concentrations of 1 nM or higher in BRAFV600E-mutant A375 cells, expression of cyclins D1/D2 or Kip1/p27 is not affected in WT BRO cells[1].

Cell Proliferation Assay[1]

Cell Line:BRAF-mutant and WT melanoma cell lines (A101D, A375, SK-MEL-28, G-361, and BRO); Colorectal cancer cell lines (COLO 205, HT-29, LS411N, and HCT-116)
Concentration:0.9-6000 nM
Incubation Time:3 days
Result:Showed a EC50range of 1-10 nM in an extended panel of BRAF-mutant human melanoma and colorectal cancer cell; while proliferation of BRAF WT cells was inhibited with EC50>1 μM.

Western Blot Analysis[1]

Cell Line:BRAFV600E-mutant A375 cells; BRAF WT, NRAS-mutant BRO (WT BRO) cells
Concentration:0.1-100 nM; 0.1-3000 nM
Incubation Time:2 hours; 24 hours
Result:Resulted in a reduction of phospho-MEK1/2 signals and cyclin D1/D2 expression in BRAFV600E-mutant A375 cells.
体内研究
(In Vivo)

BI-882370 (deliver orally; 25 mg/kg, 50 mg/kg; twice daily; 2 weeks) is efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, shows superior efficacy compared with Vemurafenib, Dabrafenib, or Trametinib[1].
BI-882370 (deliver orally; 25 mg/kg; twice daily; 40 days) developes resistance within 3 weeks, but resistance is not observed during 5 weeks of second-line therapy in combination with trametinib[1].
BI-882370 (deliver orally; 60 mg/kg; once daily; 2 weeks) indicates lack of toxicity in terms of clinical chemistry, hematology, pathology, and toxicogenomics in rats[1].

Animal Model:Human melanoma xenografts in nude mice with BRAF-mutant melanomas and colorectal carcinomas cells (A375, COLO 205; G-361, HT-29 cells)[1]
Dosage:25 mg/kg; 50 mg/kg
Administration:Deliver orally; 25 mg/kg, 50 mg/kg; twice daily; 2 weeks
Result:Regressed tumors partially, upon discontinuation, tumor regrowth was markedly delayed.
分子量

569.67

性状

Solid

Formula

C28H33F2N7O2S

CAS 号

1392429-79-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 5 mg/mL(8.78 mM;ultrasonic and warming and heat to 60℃)

H2O :< 0.1 mg/mL(insoluble)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.7554 mL8.7770 mL17.5540 mL
5 mM0.3511 mL1.7554 mL3.5108 mL
10 mM---------
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。